Introduction
The human genome is constantly challenged with DNA lesions originating from both internal and external influences (Jackson and Bartek 2009; Sirbu and Cortez 2013) . Cells can respond to DNA damage by initiating DNA repair which, if successful, allows the cell to continue its normal function. Alternatively, severe DNA damage can lead to the induction of cell death by apoptosis, or to cell cycle arrest through senescence (d'Adda di Fagagna 2008). Both radio-and chemotherapy are designed to induce apoptosis -they generate DNA modifications and oxidative damage that eventually kill the rapidly dividing tumor cells. Among the various DNA lesions, double strand breaks (DSBs) are the most dangerous because they result in a direct cleavage of the DNA backbone. DSBs occur at an estimated rate of 10 per day per cell (Lieber 2010) , their aberrant accumulation representing a major threat to genomic integrity (Jackson and Bartek 2009) . DSBs may arise from the action of ionizing radiation, oxidative free radicals, mechanical stress, topoisomerase inhibition, or other damaging influences (Lieber 2010) .
There is increasing evidence that members of the insulinlike growth factor (IGF) binding protein (IGFBP) family may influence cell responses to DNA damaging insults. Understanding the role that IGFBPs play in these processes is essential to increase knowledge both of the mechanisms by which genomic integrity is maintained in normal cell physiology, and also in the context of cancer cell sensitivity to DNAdamaging chemo-and radiotherapy. Recognition of how cell responsiveness to these therapies may be influenced by manipulating IGFBPs or their signaling pathways could lead to improved approaches to cancer treatment. The aim of this review is to provide an overview of DNA damage response pathways, with particular reference to non-homologous endjoining (NHEJ), and to discuss the involvement of IGFBPs in mediating or modulating these processes.
The IGFBPs
The insulin-like growth factors, IGF-I and IGF-II, associate in the circulation and the extracellular environment with members of the IGF binding protein (IGFBP) family, IGFBP-1 to IGFBP-6. The six high-affinity IGFBPs share cysteine-rich amino-and carboxyterminal domains, both of which contribute to the IGF-binding site (Baxter 2000; Forbes et al. 2012 ). In the circulation, IGFs have greatly extended half-lives when complexed with IGFBPs, in particular IGFBP-3 (by far the most abundant in adult human serum) and IGFBP-5, both of which form ternary complexes by interacting with a third protein, the acid-labile subunit (Baxter 2000) . In the cellular environment, IGFBP-bound IGFs have restricted access to the cell-surface type 1 IGF receptor (IGF1R), since some IGF residues involved in receptor binding also contribute to IGFBP binding (Forbes et al. 2012; Sitar et al. 2006) .
In addition to stabilizing IGFs in the bloodstream and regulating their activation of IGF1R, IGFBPs modulate cell function through interactions with other cell-surface and intracellular proteins that appear to be independent of their IGFbinding activity . Key interacting protein families include the integrins at the cell surface (Beattie, et al. 2010 ) and the nuclear hormone receptors within the nucleus (Yamada and Lee 2009 ).
IGFBPs, p53, and apoptosis
Activation of p53 is one of the key responses to DNA damage (Sperka et al. 2012) , initiating both cell cycle arrest and cell death pathways. Its phosphorylation at Ser15 by ataxiatelangiectasia mutated protein (ATM) or ataxia-telangiectasia and Rad3-related (ATR) kinases, which is followed by phosphorylation at multiple other sites, is a crucial step in the transcriptional events that follow DNA damage (Loughery et al. 2014 ). In silico prediction of genes containing p53 response elements indicates that all six IGFBP genes include such sites, located in both intronic and promoter regions of the genes (Table 1 ) (p53FamTaG, http://p53famtag.ba.itb.cnr. it) (Sbisa et al. 2007 ). Induction of IGFBPs by p53 has been shown for IGFBP-1 (Leu and George 2007) , IGFBP-2 (Grimberg et al. 2006) , and IGFBP-3 (Buckbinder et al. 1995) , and perhaps also IGFBP-5 (Kim et al. 2007) .
The link between IGFBP-1 and p53 was demonstrated in the liver of irradiated mice, in which total and phospho-p53 increased markedly 1 h post-irradiation, followed by IGFBP-1 induction (Reynolds et al. 2004 ). The increased level of IGFBP-1 was reported to counteract p53-dependent apoptosis by binding to, and blocking the mitochondrial action of, the proapoptotic protein Bak (Leu and George 2007) . IGFBP-2 was shown to be p53-dependent by the induction of IGFBP-2 mRNA in the thymus of irradiated wildtype mice, but not p53-null mice (Grimberg et al. 2006) . p53 binding to 4 intronic consensus binding sites in the IGFBP2 gene has been demonstrated, and IGFBP-2 silencing by shRNA blocked the ability of p53 to inhibit IGF-I stimulated ERK activation in prostate cancer cells (Grimberg et al. 2006 ). In the case of IGFBP-3, potential p53 binding sites were first identified in IGFBP3 intronic regions and shown to be functional (Buckbinder et al. 1995) , but hypermethylation of p53-responsive sequences in the IGFBP3 promoter region (not shown in Table 1 ) is able to selectively suppress p53-induced IGFBP-3 expression (Hanafusa et al. 2005 ). IGFBP-6, while not explicitly shown to be p53-dependent, is upregulated by DNAdamaging agents hydrogen peroxide, cisplatin, and doxorubicin (Xie et al. 2005) . These findings suggest that members of the IGFBP family may be important mediators of p53 actions.
Among the p53-regulated IGFBPs, IGFBP-3 regulation has been most extensively studied. Because IGFBP-3 can induce apoptosis in many cell types, its p53-dependent upregulation in response to DNA-damaging stimuli such as ionizing radiation is seen as an important component of the DNA damage response (Grimberg et al. 2005; Williams et al. 2000) . However, in some cell lines, IGFBP-3 is believed to be induced even in the absence of functional p53 (Butt et al. 2000; Grimberg et al. 2005) . Interestingly, in a study of chemotherapy-induced hair loss, IGFBP-3 was downregulated after cyclophosphamide treatment in p53 null mice, although upregulated when in p53 wildtype mice (Botchkarev et al. 2000) . Clearly the regulation of IGFBP-3 by p53 and its mutants is not as straightforward as originally thought, since different domains of p53 appear to be responsible for IGFBP-3 up-or downregulation (Harms and Chen 2005) . Accordingly, IGFBP3 gene promoter activity is downregulated in cells expressing some "hot-spot" mutant p53 forms, a response interpreted as a p53 gain-of function (Vikhanskaya et al. 2007 ). The variant p53 family member, ΔNp63α, has also been shown to suppress IGFBP-3 expression, leading to the suggestion that p63 overexpression by some tumors might protect them from IGFBP-3-mediated apoptosis (Barbieri et al. 2005) .
Detection and repair of double-strand breaks
Cells respond to DSB lesions by initiating the DNA damage response signaling cascade, which then activates cell cycle checkpoints and directs DNA repair. The rate and accuracy of repair depend on the clustering of the breaks and how capable the cells are of repairing the damage (Shikazono et al. 2009 ). Non-malignant cells generally have a slow turnover rate and are therefore proficient in reversing the DNA lesions and are spared from injurious damage when exposed to genotoxic insults. In malignant cells, many of which have hyperactivated DNA damage factors and rapid turnover rate, the cells' repair machinery may attempt to rejoin the DSB ends at an accelerated rate that can lead to errors in the repair process.
The DNA damage response to double-strand breaks is typically initiated in a hierarchical fashion by recruitment of ATM or DNA-dependent protein kinase (DNA-PK) to the damage sites (Falck et al. 2005) . ATR, in contrast, is recruited to single-stranded DNA. ATM and ATR activate the checkpoint kinases 1 or 2 (Chk1 or Chk2) (Abraham 2001), which in turn engage a myriad of downstream effectors that elicit an appropriate response (Smith et al. 2010; Zhou and Elledge 2000) . The structurally-related transducer kinases heading the DNA damage response -ATM, ATR, and the catalytic subunit of DNA-PK (DNAPKcs) -are all members of the PI3 kinase-related kinases (PIKK) family of Ser/Thr kinases (Abraham 2004).
DSB repair pathway choice
The mammalian genome has evolved two efficient, cell-cycle dependent DSB repair pathways -homologous recombination (HR) and non-homologous end-joining (NHEJ) (Thompson 2012) . These pathways are complementary and operate under different circumstances. HR repair is a relatively slow, errorfree process that occurs only during post-replicative S and G2 phases of the cell cycle during which a homologous DNA template (sister chromatid) is available (Moynahan and Jasin Filippo et al. 2008) . HR machinery copies the missing information from this DNA template into the break site, resulting in an exact reconstitution of the original sequence. In contrast, NHEJ repair rejoins two broken ends, with less stringency for homology, resulting in an intrinsically error-prone process. Repair errors can lead to gene mutations or wider chromosomal rearrangements. The lack of requirement for a homologous template (sister chromatid) means that NHEJ is not restricted to a certain phase of the cell cycle despite being assumed as the dominant repair pathway during the G1 and M phases (Weterings and Chen 2008) . Malignant cells typically have fast turnover rates and, therefore, preferentially repair DSBs via the NHEJ pathway; if rapid re-joining does not occur, then resection may occur promoting HR repair (Shibata et al. 2011; Woods and Turchi 2013 ). It appears that the two DSB repair pathways, HR and NHEJ are in direct competition -the HR (Mre11, Rad50 and Nbs1, or MRN) and NHEJ (Ku70/Ku80) sensors both bind independently yet almost simultaneously to the same DNA termini. During the late S/G2 phase where both NHEJ and HR repair mechanisms can co-exist, NHEJ is typically favored over HR because damage recognition by Ku70/80 precedes that of MRN (Kakarougkas and Jeggo 2014) . Reduced activity of NHEJ proteins allows the process of DNA-end resection, in which the 5′-end of a damaged DNA strand is partially degraded, to occur, facilitating HR (Huertas 2010; Shibata et al. 2011 ). Recent studies have also shown that transient, PARP-dependent recruitment of RNA-binding proteins NONO and SFPQ to damaged sites can suppress HR repair whereas NHEJ is increased (Krietsch et al. 2012; Salton et al. 2010) . Nevertheless if NHEJ progression is impeded, either due to high chromatin compaction or damage complexity, HR may still be activated to undertake the repair (Kakarougkas and Jeggo 2014) .
Non-homologous end-joining
NHEJ begins with the recruitment and high-affinity binding of the abundant Ku heterodimer to DSB ends (Lieber 2010) . Ku consists of Ku70 and Ku80 subunits that constitute the DNAbinding component of DNA-PK. High-affinity binding is conferred by the toroidal structure of Ku70/Ku80 that encircles about 20 bp of DNA (Grundy et al. 2014) . By forming a synapse between broken DNA ends, the Ku heterodimer functions as a scaffold to support and align the DNA ends, while making the termini accessible to nucleases, polymerases, and ligases to promote the end-joining (Nick McElhinny et al. 2000) .
A key binding partner of the Ku heterodimer is the ∼465 kDa kinase, DNA-PKcs (Meek et al. 2004; Uematsu et al. 2007 ). Autophosphorylation of DNA-PKcs upon binding to the DNA:Ku scaffold is required for the efficient repair of DSBs via the NHEJ pathway ). In its dormant, unphosphorylated form, DNA-PKcs blocks the access of processing enzymes and ligases to the DNA ends, perhaps owing to its very large size. This block needs to be r e l i e v e d b e f o r e N H E J r e p a i r c a n p r o g r e s s . Autophosphorylation of DNA-PKcs at SQ/TQ motifs -namely the 2609 (or ABCDE) cluster, the 2056 (PQR) cluster and C-terminal residues -releases the cap and allows processing and ligation of the broken ends to proceed (Davis et al. 2014; Dobbs et al. 2010 ). Phosphorylation at the Ser2056 cluster is mediated by DNA-PKcs itself , while phosphorylation at the Thr2609 cluster is mediated by ATM ).
These phosphorylations enable DNA end-processing and recruitment of the ligation complex, which encompasses DNA ligase IV, X-ray repair cross-complementing protein 4 (XRCC4) and XRCC4-like factor (XLF; also termed Cernunnos) (Cottarel et al. 2013) . The recruitment of this complex to the Ku-DSB scaffold is facilitated by DNAPKcs. Most DNA termini are, however, incompatible -at least one of the strands will possess either a 3′ or 5′ single strand overhang -and, therefore, require additional processing to remove the non-ligatable ends. Candidate processing enzymes include the DNA polymerase μ and λ (polμ and polλ), terminal deoxynucleotidyltransferase, and the polynucleotide kinase (PNK) (Bernstein et al. 2009; Lieber 2010; Pawelczak et al. 2011) . The endonuclease Artemis is also required for resecting a subset of DNA ends, especially the 3′-phosphoglycate ends commonly incurred by radiation. This Artemis endonuclease activity is facilitated by both DNAPKcs and ATM (Pawelczak et al. 2011; Riballo et al. 2004 ).
Involvement of EGFR in the DNA damage response
DNA damage can trigger mitogenic growth factor signaling cascades, including activation of the epidermal growth factor receptor (EGFR). EGFR is a 170 kDa receptor tyrosine kinase involved in many physiological processes in both normal and malignant cells. EGFR overexpression occurs in many cancers, e.g. up to 50 % of triple negative breast cancers (Pintens et al. 2009 ) and may be associated with poor prognosis (Viale et al. 2009 ). These observations are the basis for a number of clinical trials that are exploring the efficacy of monoclonal anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in breast cancer, as well as lung cancer and other forms of malignancy. In addition to activation of the EGFR by ligands such as EGF and TGFα, EGFR can be activated by DNAdamaging stimuli such as ionizing radiation and certain cytotoxic drugs (Kriegs et al. 2010) , through mechanisms that are not fully established, but may involve the tyrosine kinase Src (Dittmann et al. 2008 ). This activation results in caveolin-1-dependent endocytosis and nuclear localization of EGFR (Dittmann et al. 2008; Khan et al. 2006 ). Nuclear EGFR has been shown to interact with both the catalytic and regulatory (Ku70/Ku80) subunits of DNA-PK, resulting in activation of the DNA-PK complex and favoring NHEJ repair (Dittmann et al. 2005 ). The phosphorylated DNA-PK clusters include 2056 and 2609, and in particular Thr2609 phosphorylation of DNA-PKcs is critical for EGFR-mediated radiation resistance (Javvadi et al. 2012) . EGFR inhibition and/or downregulation by monoclonal antibodies abolishes EGFR nuclear translocation and, as a consequence, DNA-damage-induced DNA-PK activation (Dittmann et al. 2005) . Similarly, the EGFR kinase inhibitor gefitinib was found to inhibit the formation of nuclear EGFR-DNA-PKcs complexes .
EGFR canonically triggers both the pro-survival PI3K/AKT pathway and the mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinase (ERK) pathway (Chen and Nirodi 2007) . Both cytoplasmic signaling pathways appear to be involved in NHEJ and HR repair, potentially contributing to radioresistance (Golding et al. 2009 ). Akt has a role in phosphorylation of DNA-PKcs at the Ser2056 and Thr2609 clusters (Toulany et al. 2008 ) and, reciprocally, Akt can be activated by DNA-PKcs, providing a pro-survival feedback (Bozulic et al. 2008 ). This suggests that Akt and DNA-PKcs are inter-dependent for their maximal response to DNA damage. In parallel, in response to radiation, the EGFR/MEK/ERK signaling pathway is crucial for efficient HR and maximal activation of ATM (Golding et al. 2007 ). Taken together, either over-abundance of nuclear EGFR or activation of PI3K/AKT and/or MAPK/ERK signaling pathways induced by DNA-damaging therapies leads to an overdrive in DNA damage repair, which plays an important role in the resistance to chemo-and radiotherapy in breast and other cancer patients.
IGFBPs and the DNA damage response
There is limited literature on the involvement of IGFBPs in DNA DSB induction and signaling. Nevertheless evidence can be derived from studies investigating IGFBP effects on DNA-damaging agents, including chemotherapy, radiotherapy, UV irradiation, and reactive oxygen species. IGFBP-3 can directly mediate or accentuate apoptotic cell death by DNAdamage-associated agents such as ceramide (Gill et al. 1997) , UV radiation (Hollowood et al. 2000) , paclitaxel (Fowler et al. 2000) , etoposide (Drivdahl et al. 2001; Lin et al. 2014 ) and doxorubicin (Granata et al. 2003) . IGFBP-3 upregulation was shown to be associated with radiosensitive, compared to radioresistant, cervical cancer cell lines (Achary et al. 2000) , and a similar observation has been reported in esophageal cancer cells (Yoshino et al. 2011) . Similarly, increased expression of IGFBP-3 was associated with enhanced sensitivity to the cytotoxic effects of cisplatin in esophageal cancer, and this was reversed by silencing of IGFBP-3 (Zhao et al. 2012) . These effects of IGFBP-3 may in some cases be dependent on its inhibition of prosurvival IGF1R signaling by sequestering IGFs, although the possibility of chemo-or radiosensitizing effects without interference in IGF1R signaling cannot be excluded. Other IGFBPs may have opposite effects; for example, notwithstanding the reported p53-dependence of IGFBP-2, exogenous IGFBP-2 was found to decrease the glioma cell response to the DNA-damaging drug temozolomide (Han et al. 2014 ),
The involvement of sphingolipids
Ceramide accumulation, resulting from both ceramide synthase activation (de novo synthesis) and sphingomyelin breakdown, has been extensively documented as a response to cell irradiation leading to apoptotic cell death (Aureli et al. 2014) . Cells isolated from mice that are deficient in acid sphingomyelinase, an important enzyme in sphingomyelin catabolism to ceramide, show resistance to radiation-induced apoptosis, and sensitivity is restored when the enzyme is reintroduced (Santana et al. 1996) . IGFBP-3 potentiation of doxorubicin-induced apoptosis in human endothelial cell cultures was shown to be accompanied by an increase in ceramide levels, and inhibited by the ceramide synthase inhibitor fumonisin B1, suggesting that in these cells, IGFBP-3-dependent de novo synthesis of ceramide was an important contributor to doxorubicin-induced cell death (Granata et al. 2004) .
Breast cancer cell death induced by exogenous C2 ceramide (a cell-permeable ceramide analogue) was found to be enhanced by exogenous recombinant IGFBP-3, but inhibited by recombinant IGFBP-4 or IGFBP-5 (Perks et al. 1999) . IGFBP-1, -2 and -6 had no effect. The enhancing effect of exogenous IGFBP-3 on ceramide-dependent cell death appeared unrelated to its ability to sequester IGFs (which could activate IGF1R-mediated cell survival), since an IGFBP-3 analogue with greatly reduced IGF-binding affinity had a similar effect (Perks et al. 2002) . The protective effect of IGFBP-5 was reversed by the addition of a hexapeptide containing the Arg-Gly-Asp integrin-binding motif, suggesting that the cellular environment is an important modulator of its response. In contrast to the protective effect of exogenous IGFBP-5 against ceramide-induced apoptosis, endogenous IGFBP-5 expressed by an adenoviral vector in breast cancer cells induced apoptosis alone, and enhanced radiation-induced loss of cell survival, but ceramide levels were not measured in this experiment (Butt et al. 2003) .
While some studies suggest that IGFBP-3 may contribute to apoptosis by inducing pro-apoptotic ceramide under DNAdamaging conditions, there is also the potential for IGFBP-3 to promote resistance to chemotherapies via its upregulation of the pro-survival arm of this sphingolipid signaling system, the key components of which are sphingosine kinase (SphK) and the product of its enzymatic activity, sphingosine-1-phosphate (S1P). IGFBP-3 induction of SphK1 expression and activity was first reported in human endothelial cells (Granata et al. 2004) where it was shown to mediate cellsurvival effects of IGFBP-3. Upregulation of this pathway by IGFBP-3 was also demonstrated in estrogen receptornegative breast epithelial cells and several triple-negative breast cancer cell lines Martin et al. 2009 ), in which IGFBP-3-induced S1P enhances EGFR signaling via receptor transactivation. In view of the fact that SphK1 and S1P promote chemo-and radio-resistance in a number of cell and animal models of cancer (Pchejetski et al. 2008; Truman et al. 2014) , it is possible that through its induction of this pathway, and its interaction with EGFR to promote DNA damage repair, IGFBP-3 contributes to resistance to therapies that work by damaging DNA. This could be particularly relevant in cancer types with high IGFBP-3 expression, such as estrogen receptor-negative breast cancers (Shao et al. 1992) , pancreatic cancer (Xue et al. 2008) , and clear cell renal cell carcinoma (Chuang et al. 2008) .
A role of IGFBP-3 in non-homologous end-joining IGFBP-3 was shown several years ago to be a substrate for DNA-PKcs (Schedlich et al. 2003) which, as noted above, is a key component of the NHEJ pathway. Phosphorylation of IGFBP-3 by DNA-PKcs resulted in a loss of IGF-binding, but increased nuclear translocation and retention. A similar enhancement of nuclear import by DNA-PK phosphorylation was previously shown for SV40 large T-antigen (Xiao et al. 1997) . The target site on IGFBP-3 for DNA-PK phosphorylation was inferred by mutagenesis to be Ser156, one of 3 clustered consensus sites for this family of kinases (Ser156, Ser165, and Thr170), and mutation of this residue prevented IGFBP-3-induced apoptosis in prostate cancer cells (Cobb et al. 2006) . Conversely, IGFBP-3 phosphorylation by protein kinase CK2, while having little effect on the rate of nuclear uptake of IGFBP-3 (Schedlich et al. 2003) , was shown to inhibit its apoptotic effect, and preventing CK2 activation enhanced apoptosis induced by IGFBP-3 (Cobb et al. 2009 ). These responses may be functionally related since CK2 downregulation has been shown to markedly increase DNA-PKcs activity (Olsen et al. 2010) . However, the dependence of IGFBP-3 on DNAPKcs phosphorylation of Ser156 for its proapoptotic effect in prostate cancer cells contrasts with an observation made in retinal endothelial cells, in which mutation of this residue to prevent its phosphorylation by DNA-PKcs increased the apoptotic response (Zhao et al. 2012) . In this experimental system, DNA-PK was shown to contribute to the ability of IGFBP-3 to enhance cell survival, rather than death.
The idea that IGFBP-3 may promote survival rather than apoptosis under some conditions has strong experimental support. Although it appears to function as a tumor suppressor in some cancers, high IGFBP-3 expression is a poor prognostic feature in some other tumor types. IGFBP-3 has also been shown to have growth-promoting activity in a number of cell culture studies (Baxter 2014). These disparate observations Fig. 1 Involvement of IGFBP-3 in the DNA damage response. IGFBP-3 interacts with EGFR in lipid rafts and, in response to a DNA-damaging stimulus, translocates to the nucleus where both proteins complex with DNA-PK to facilitate non-homologous end-joining. This effect is blocked by EGFR kinase inhibition. IGFBP-3 promotes survival by inhibiting the production of pro-apoptotic ceramide, and increasing sphingosine-1-phosphate, but in response to genotoxic stress, it can increase apoptosis by activating ceramide synthesis. SMase, sphingomyelinase; SphK, sphingosine kinase; S1P, sphingosine-1-phosphate raise the possibility that IGFBP-3 may stimulate cell proliferation and/or survival pathways under some conditions. The observation of enhanced nuclear entry by IGFBP-3 in response to phosphorylation by DNA-PKcs suggests that nuclear IGFBP-3 might be involved in DNA-PK-dependent DNA damage repair (Fig. 1) . This has been investigated in triplenegative breast cancer cell lines that have high IGFBP-3 expression. In MDA-MB-468 cells, that have particularly high IGFBP-3 production, the formation of nuclear complexes between DNA-PKcs and EGFR in response to etoposide treatment was found to be inhibited by the EGFR kinase inhibitor, gefitinib, suggesting that they were dependent on EGFR autophosphorylation at Tyr1068 ). These nuclear complexes also appear to include IGFBP-3, since gefitinib also inhibited the formation of nuclear DNA-PKcs-IGFBP-3 and EGFR-IGFBP-3 complexes, as demonstrated both by coimmunoprecipitation studies and by direct visualization using the proximity ligation assay.
However, whereas complexes between DNA-PKcs and IGFBP-3 were found almost exclusively within the nucleus by confocal microscopy, those between EGFR and IGFBP-3 had a significant extranuclear presence . The complexes initially appeared associated with lipid rafts, but this co-localization decreased 2-4 h after etoposide treatment, consistent with their translocation to the nucleus (Fig. 1) . IGFBP-3 silencing by either of two siRNAs decreased the DNA-PKcs autophosphorylation response to etoposide, the formation of nuclear EGFR-DNA-PKcs complexes, and the repair of DNA by NHEJ, as measured by a direct assay using nuclear extracts . These findings suggest an integral role for IGFBP-3 in the events following exposure of breast cancer cells to DNA double-strand breaks, eventually leading to DNA repair.
Although direct binding between IGFBP-3 and DNA-PKcs has been observed, no interaction between IGFBP-3 and the Ku70/80 subunits of the DNA-PK complex has been reported. In contrast, both Ku70 and Ku80 have been purified by affinity with IGFBP-6, and Ku80 was shown to have a highaffinity interaction with IGFBP-6 (Iosef et al. 2010 ). IGFBP-6 overexpression decreased the association of Ku70/80 with DNA ends, suggesting that it might be inhibitory to DNA repair by NHEJ, in contrast to IGFBP-3 which appears to participate in this process.
Concluding comments
The regulation of DNA damage repair is of considerable interest clinically because it is an important mechanism by which cancer cells resist the actions of chemotherapy and radiotherapy, but it is also of much broader interest considering that DNA damage occurs in all cells every day. The observations that all of the IGFBP genes have p53 binding sites, and that several of the IGFBPs are functionally inducible by p53 activation, have provided important clues that this family of proteins might play integral roles in cell responsiveness to genotoxic stress. It is perhaps surprising that, to date, there have been few explicit demonstrations of IGFBPs fulfilling these roles, despite an increasing body of literature suggesting the possibility of direct or indirect involvement. The evidence is certainly strongest for IGFBP-3, the IGFBP that is most abundant in adult humans and also the most extensively studied for its diverse IGF-dependent and -independent actions.
How might the involvement of IGFBPs in DNA repair mechanisms be exploited for therapeutic advantage? It seems unlikely that the IGFBPs themselves would be ideal targets, as it may be difficult to distinguish therapeutically between their dual endocrine and autocrine roles. A more focused approach may be to discover and target key intracellular interactions between IGFBPs and other effector proteins; in the case of IGFBP-3 or IGFBP-6 this might be their interaction with components of the DNA-PK complex. Since mutations in IGFBP genes are relatively rare, biochemical discovery tools (e.g. proteomics) are likely to be more effective at uncovering novel interactions involved in DNA repair than the genetic approaches that have revealed the involvement of many other components of DNA repair complexes. Regardless of the discovery technique, increased knowledge of the involvement of IGFBPs in the cancer cell response to DNA damage will not only improve understanding of the ways in which cells maintain genomic integrity, but may also yield unexpected benefits in the form of new cancer therapy.
